ROCHESTER, N.Y., APRIL 21, 2015. VirtualScopics, Inc. (NASDAQ:VSCP), a leading provider of clinical trial imaging solutions, announces that they have implemented the imaging data and query management digital platform, TrialTracker™ that was licensed from alliance partner, IXICO plc, in December 2014. Operational metrics from the initial clinical trials that have been deployed using TrialTracker™ have met or exceeded all expectations for performance.
“Imaging sites are at the heart of all clinical trials for VirtualScopics,” said Ron Way, Vice President of Operations at VirtualScopics. “Providing sites with the very best tools for safe, reliable and efficient transfer of this precious research information is why we chose to work with IXICO, and to deploy TrialTracker™ and Site Interface. We expect our deployment to accelerate very quickly, now that our proof points have been met.”
Data Queries are a necessary though burdensome part of almost every clinical trial. Sites using TrialTracker Site Interface can now manage their entire set of image data transfer activities, including transfer dates, compliance with privacy regulations governing personal health information (PHI) and resolution of data queries with a single intuitive application.
“When you make it easier for sites to work with you,” explained Mr. Way, “the outcomes include a faster turnaround time from acquisition to image transfer, a reduced number and faster resolution of data queries as well as substantial reductions in elapsed time before image analysis can begin. That’s a win for the sites, a win for VirtualScopics and most importantly, a big win for our sponsors.”
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA Issues Complete Response Letter to Replimune for RP1 Combination Therapy in Advanced Melanoma
July 22nd 2025The FDA’s complete response letter cited concerns that the Phase I/II IGNYTE (NCT03767348) trial in advanced melanoma was not an adequate, well-controlled study and that its heterogeneous patient population limited interpretability, preventing approval in its current form.